CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
The theme of EHC 2025 (Lisbon, Portugal, 3-6 December 2025) was ‘Transforming Challenges into Solutions’, with delegates attending in person and online to discuss latest research and practical strategies for improving patient care.
Primary data from the Phase 3 ECLIPSE trial in patients with migraine with or without aura have shown that atogepant 60 mg was superior to placebo in achieving pain freedom at 2 hours post dose. In the study, 148/602 (24.3%) of atogepant-treated participants were pain free at 2 hours compared to 80/612 (13.1%) of those …
Read more »Leading international migraine specialists have proposed new definitions of a migraine day to the International Headache Society for inclusion in the International Classification of Headache Disorders (ICHD).1The aim is to standardise definitions used in clinical trials and clinical practice and avoid the variability in terminology highlighted in a recently published analysis of Phase 3 clinical …
Read more »Switching patients who have failed on a first CGRP mAb to a second CGRP mAb or a gepant achieves similar outcomes, with a trend towards a higher clinical response and better tolerability with a gepant, according to results of a retrospective observational study of patients treated at a tertiary Headache Unit in Spain between May …
Read more »Ubrogepant maintains comparable efficacy and safety profiles irrespective of concurrent CGRP mAb use, according to results of the Phase 4 UNION trial. In the prospective, open label study, 165 participants were randomised to ubrogepant 50 mg or 100 mg, either alone or in combination with a CGRP mAb. In patients taking ubrogepant 50 mg or …
Read more »Women who use CGRP mAbs during pregnancy may be at increased risk of hypertensive disorders and pre-eclampsia, though wide confidence intervals for risk ratios (RRs) make it difficult to draw firm conclusions. This is the main finding from a population-based study of women with chronic migraine registered in the nationwide Medical Birth Registry of Norway …
Read more »An analysis of long term efficacy of CGRP mAbs in 223 patients with chronic or episodic migraine (62% and 29% respectively) or new daily persistent headache with migraine phenotype (9%), at a large UK centre has shown that approximately three quarters had a >30% response and this was most likely in triptan responders and older …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
